2010年1月英国医疗设备行业研究报告

是 否 +2 论坛币

k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群

赵安豆老师微信：zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

立即领取

感谢您参与论坛问题回答

经管之家送您两个论坛币！

+2 论坛币

【出版时间及名称】：2010年1月英国医疗设备行业研究报告
        【作者】：德意志银行
        【文件格式】：PDF
        【页数】：122
        【目录或简介】：

Table of Contents
Executive summary ........................................................................... 5
Sector to benefit from positive structural changes ...................................................................5
Perform. of some Cos. could still be driven by cyclical factors.................................................7
Sector P/E multiple largely fair ..................................................................................................7
Hearing devices ................................................................................. 9
2010E: an eventful year.............................................................................................................9
Key moving parts to be a net positive for earnings...................................................................9
Sonova to outperform W. Demant..........................................................................................10
Sonova.............................................................................................. 11
Upgraded to Buy.....................................................................................................................11
Existing business to exceed expectations ..............................................................................12
New businesses to increase Sonova’s targetable market opportunities materially ................13
InSound Medical: a key win for HAs .......................................................................................15
Advanced Bionics Corp: a substantial start in hearing implants ..............................................17
Valuation ................................................................................................................................19
Price Target............................................................................................................................20
Risks ......................................................................................................................................20
Forecasts ...............................................................................................................................21
W. Demant........................................................................................ 25
Some scope to appreciate ......................................................................................................25
Hearing aid sales to return to robust growth ..........................................................................26
First full year in the bone anchored hearing implant market ...................................................28
Diagnostic instruments to continue share gains .....................................................................29
Personal communication to normalise....................................................................................29
Margins to recover further ......................................................................................................29
Valuation ................................................................................................................................30
Price Target............................................................................................................................31
Risks ......................................................................................................................................31
Forecasts ...............................................................................................................................32
Modern tooth restorations and replacements.............................. 37
2010E: A year of market share gains ......................................................................................37
WW modern tooth replacement trends and outlook ..............................................................38
WW modern tooth restoration trends and outlook .................................................................40
Straumann........................................................................................ 41
Continue to gain market share ................................................................................................41
Gaining further dental implant market share ...........................................................................42
Expanding presence in the dental regeneration market ..........................................................44
Broadening its restoration offerings........................................................................................46
Pick-ups in Asia to remain limited in 2010...............................................................................47
Some margin expansion .........................................................................................................47
Substantial EPS upgrades possible.........................................................................................48
Valuation ................................................................................................................................49
Price Target............................................................................................................................50
Risks ......................................................................................................................................50
Forecasts ...............................................................................................................................51
Table of Contents (Cont'd)
Nobel Biocare................................................................................... 55
Re-gaining market share .........................................................................................................55
Material re-invigoration of PROCERA......................................................................................56
NobelActive™ to exceed expectations ...................................................................................58
Benefits of stronger customer relationships and sales force..................................................58
Efficiency initiatives and sales growth to expand margins......................................................59
2010E earnings could be much better than expected.............................................................60
Valuation ................................................................................................................................61
Price Target............................................................................................................................62
Risks ......................................................................................................................................62
Forecasts ...............................................................................................................................63
Smith & Nephew ............................................................................. 67

扫码加我 拉你入群

请注明：姓名-公司-职位

以便审核进群资格，未注明则拒绝

分享0 收藏0 回帖

关键词：行业研究报告 医疗设备 研究报告 行业研究 Expectations 研究报告 英国 行业 医疗 设备

A more robust year .................................................................................................................67
Orthopaedics ..........................................................................................................................68
(2010E: sales of $2,252m, 56% of gp; EBITA of $574m, 60% of gp).....................................68
Endoscopy ..............................................................................................................................72
(2010E: sales of $834m, 21% of gp; EBITA of $195m, 20% of gp)........................................72
Advanced Wound Management (AWM).................................................................................73
(2010E: sales of $892m, 22% of gp; EBITA of $194m, 20% of gp)........................................73
Potential of some benefits of cyclical recoveries....................................................................76
Valuation ................................................................................................................................79
Price Target............................................................................................................................82
Risks ......................................................................................................................................82
Forecasts ...............................................................................................................................83
Coloplast .......................................................................................... 89
Prepare for profitable growth..................................................................................................89
Ostomy ..................................................................................................................................91
(2009/10E: 41% of group sales)..............................................................................................91
Continence care (CC) & urology (U) ........................................................................................94
(2009/10E: 42% of group sales)..............................................................................................94
Wound & Skin Care.................................................................................................................96
(2009/10E: 17% of group sales)..............................................................................................96
Further profitability improvements..........................................................................................97
Marginal benefits of cyclical upturn ........................................................................................99
Valuation Coloplast................................................................................................................100
Price Target..........................................................................................................................101
Risks ....................................................................................................................................101
Forecasts ..............................................................................................................................102
Synthes........................................................................................... 107
Some scope of outperformance in early 2010E....................................................................107
Continue to strengthen market positions..............................................................................108
Strong balance sheet with mounting cash balances.... .........................................................108
Reimbursement rates to be scrutinised closely....................................................................110
Earnings could benefit modestly from an economic upturn .................................................111
Op. improvements to counter deteriorating fundamentals ................................................... 113
Valuation ...............................................................................................................................115
Price Target..........................................................................................................................116
Risks ....................................................................................................................................116
Forecasts ..............................................................................................................................117

채용에서 대기업에 비해 현저히 불리한 중소기업들이 좋은 인재를 확보
하고 경쟁력을 높여 나가기 위해서는 채용활동에서 지금보다 훨씬 더 많
은 관심과 노력을 기울일 필요가 있다.

简直是天价！根本不是怀着互相学习的态度啊